Chiasma Complete Response From FDA Could Delay Mycapssa Substantially
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA recommends a randomized, double-blind controlled pivotal trial for approval of the oral somatostatin analogue, which was filed for approval under the 505(b)(2) pathway last August.